There are currently 1477 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Schizophrenia
Register for Updates
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
NCT06538116
Recruiting
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/22/2025
Locations: Kerwin Medical Center, Dallas, Texas
Conditions: Alzheimer Disease
Register for Updates
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928
Recruiting
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: Cedar Health Research, LLC, Dallas, Texas
Conditions: Migraine
Register for Updates
A Study of Remternetug (LY3372993) in Healthy Participants
NCT07056309
Recruiting
The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/22/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas
Conditions: Healthy
Register for Updates
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Embolization, Portal Vein Embolization
Register for Updates
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
NCT06568042
Recruiting
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Cedar Health Research, Dallas, Texas
Conditions: Neuropathic Pain, Distal Sensory Polyneuropathy
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
NCT06883305
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/22/2025
Locations: Research Site, Dallas, Texas
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419
Recruiting
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas
Conditions: Healthy, Overweight, Obesity, Type 2 Diabetes
Register for Updates
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872
Recruiting
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas, Texas +1 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
NCT06924021
Recruiting
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/21/2025
Locations: Retina Foundation of the Southwest, Dallas, Texas
Conditions: Age-Related Macular Degeneration
Register for Updates
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515
Recruiting
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/21/2025
Locations: Baylor Scott and White, Dallas, Texas
Conditions: Acute Decompensated Heart Failure
Register for Updates
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
NCT06620003
Recruiting
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2025
Locations: Synexus Clinical Research US; Inc., Dallas, Texas
Conditions: Marburg Virus Disease
Register for Updates